Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
A Randomised, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Parallel Group Efficacy and Safety Comparison of 12-Week Treatment of Two Doses [5 μg (2 Actuations of 2.5 μg) and 10 μg (2 Actuations of 5 μg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Placebo and Ipratropium Bromide Inhalation Aerosol (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
| NCT number | NCT00239473 |
| Other study ID # | 205.251 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 3 |
| First received | October 14, 2005 |
| Last updated | October 31, 2013 |
| Start date | November 2002 |
| Verified date | October 2013 |
| Source | Boehringer Ingelheim |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratropium bromide MDI four times daily in patients with COPD. The secondary objective was to compare the safety of tiotropium inhalation solution delivered by the Respimat to placebo and ipratropium bromide MDI.
| Status | Completed |
| Enrollment | 429 |
| Est. completion date | |
| Est. primary completion date | December 2003 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 40 Years and older |
| Eligibility | Outpatients of either sex, aged >/= 40 years with a diagnosis of COPD (FEV1 </= 60% predicted [ECCS criteria] and FEV1/FVC </= 70%) |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Germany | Boehringer Ingelheim Investigational Site | Berlin | |
| Germany | MEDARS GmbH | Berlin | |
| Germany | Boehringer Ingelheim Investigational Site | Bonn | |
| Germany | Boehringer Ingelheim Investigational Site | Frankfurt/Main | |
| Germany | Inamed Research GmbH & Co. KG | Gauting | |
| Germany | Pneumologisches Forschungsinstitut GmbH | Großhansdorf | |
| Germany | Pneumologisches Forschungsinstitut GmbH am Krankenhaus | Hamburg | |
| Germany | Boehringer Ingelheim Investigational Site | Hannover | |
| Germany | Universitätsklinikum Schleswig-Holstein | Kiel | |
| Germany | ClinPharm International GmbH & Co. KG | Leipzig | |
| Germany | Neurologische Klinik der Otto-von-Guericke-Universität | Magdeburg | |
| Germany | Johannes-Gutenberg-Universität Mainz | Mainz | |
| Germany | Boehringer Ingelheim Investigational Site | Minden | |
| Germany | Medizinische Klinik III | Moers | |
| Germany | Boehringer Ingelheim Investigational Site | München | |
| Germany | Abt. Lungen- und Bronchialheilkunde | Schmallenberg | |
| Germany | Boehringer Ingelheim Investigational Site | Steinfurt | |
| Italy | Ospedale Generale Provinciale Mazzoni | Ascoli Piceno | |
| Italy | Dip. di Medicina Interna e Medicina Specialistica | Catania | |
| Italy | U. O. di Fisiopatologia Respiratoria | Ferrara | |
| Italy | Ospedale S. Martino | Genova | |
| Italy | U. O. di Pneumologia e Servizio di Fisiopatologia Resp. | Milano | |
| Italy | IRCCS Policlinico San Matteo | Pavia | |
| Italy | U. O. C di Pneumologia | Roma | |
| Italy | Ospedale Silvestrini | San Sisto (pg) | |
| Italy | U. O. di Pneumologia | Trieste | |
| South Africa | Hydromed Hospital | Bloemfontein | |
| South Africa | UCT Lung Institute | Cape Town | |
| South Africa | 1 Military Hospital | Pretoria | |
| South Africa | Tygerberg Hospital | Tygerberg | |
| Switzerland | Universitätskliniken Basel | Basel | |
| Switzerland | Ospedale San Giovanni | Bellinzona | |
| Switzerland | Boehringer Ingelheim Investigational Site | Davos | |
| Switzerland | Boehringer Ingelheim Investigational Site | Laufen | |
| Switzerland | Boehringer Ingelheim Investigational Site | Locarno | |
| Switzerland | Ospedale Regionale | Lugano | |
| Switzerland | Boehringer Ingelheim Investigational Site | Münchenstein | |
| Switzerland | Kantonsspital St. Gallen | St. Gallen |
| Lead Sponsor | Collaborator |
|---|---|
| Boehringer Ingelheim |
Germany, Italy, South Africa, Switzerland,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Trough FEV1 response | after 12 weeks | No | |
| Secondary | Trough FEV1 response | after 1, 4 and 8 weeks | No | |
| Secondary | Trough FVC response | after 1, 4, 8 and 12 weeks | No | |
| Secondary | FEV1 and FVC area under the curve (AUC)0-6h and peak response | after 0, 1, 4, 8 and 12 weeks | No | |
| Secondary | Individual FEV1 and FVC measurements | during 12 weeks | No | |
| Secondary | Onset and duration of therapeutic response and percentage of responders | after 0 and 12 weeks | No | |
| Secondary | Weekly mean pre-dose morning and evening PEFR (peak expiratory flow rate) | up to 12 weeks | No | |
| Secondary | Weekly mean number of occasions of rescue therapy used per day (PRN salbutamol) | up to 12 weeks | No | |
| Secondary | COPD symptom scores (wheezing, shortness of breath, coughing and tightness of chest) | up to 15 weeks | No | |
| Secondary | Physician's Global Evaluation | up to 15 weeks | No | |
| Secondary | Number of patients with at least one exacerbation of COPD | up to 15 weeks | No | |
| Secondary | Time to first exacerbation | up to 15 weeks | No | |
| Secondary | Number of exacerbations and exacerbation days | up to 15 weeks | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
| Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
| Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
| Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
| Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
| Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
| Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
| Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
| Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
| Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
| Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
| Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
| Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
| Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
| Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
| Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|